Alexander Maxwell
Value, growth, long-term horizon, biotech

Titan: A Compelling Investment Trading Below Fair Value And A Potential Buyout By Its Partner

Titan Pharmaceuticals (NASDAQ:TTNP) is a very interesting investment opportunity. Coming off of the bad news of an FDA Complete Response Letter regarding its lead drug compound Probuphine, the company once again looks like a rather attractive buy opportunity. It is in the beginning of conducting a clinical trial that should set the stage for FDA approval, and could be a possible takeover target should the company successfully obtain FDA approval. These events should be very lucrative for Titan shareholders and makes it appear as though Titan is largely undervalued given its long term growth potential. The purpose of this article is to discuss the current developments and potential for Titan's pipeline, and then to develop a fair value...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details